These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 25261844)

  • 41. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients.
    Kim JT; Lee DH; Joe SG; Kim JG; Yoon YH
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3378-84. PubMed ID: 23611988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
    Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
    Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
    Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
    Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
    Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
    Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab.
    Jeon S; Lee WK
    Retina; 2014 Aug; 34(8):1606-11. PubMed ID: 24553409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.
    Wu L; Hernandez-Bogantes E; Roca JA; Arevalo JF; Barraza K; Lasave AF
    Retina; 2011 Feb; 31(2):298-303. PubMed ID: 21099452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Macular hypotrophy after internal limiting membrane removal for diabetic macular edema.
    Romano MR; Romano V; Vallejo-Garcia JL; Vinciguerra R; Romano M; Cereda M; Angi M; Valldeperas X; Costagliola C; Vinciguerra P
    Retina; 2014 Jun; 34(6):1182-9. PubMed ID: 24846134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema.
    Santos AR; Gomes SC; Figueira J; Nunes S; Lobo CL; Cunha-Vaz JG
    Ophthalmologica; 2014; 231(1):16-22. PubMed ID: 24280908
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Refractive changes after pharmacologic resolution of diabetic macular edema.
    Deák GG; Lammer J; Prager S; Mylonas G; Bolz M; Schmidt-Erfurth U;
    Ophthalmology; 2014 May; 121(5):1054-8. PubMed ID: 24439462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
    Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY
    Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diameter of retinal vessels in patients with diabetic macular edema is not altered by intravitreal ranibizumab (lucentis).
    Terai N; Haustein M; Siegel A; Stodtmeister R; Pillunat LE; Sandner D
    Retina; 2014 Jul; 34(7):1466-72. PubMed ID: 24457978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Bloch SB; Lund-Andersen H; Sander B; Larsen M
    Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
    Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S
    Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group.
    Wu L; Arevalo JF; Hernandez-Bogantes E; Regatieri CV; Roca JA; Farah ME
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):366-71. PubMed ID: 23215543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regional Choroidal Thickness Changes in Branch Retinal Vein Occlusion with Macular Edema.
    Kim KH; Lee DH; Lee JJ; Park SW; Byon IS; Lee JE
    Ophthalmologica; 2015; 234(2):109-18. PubMed ID: 26305536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Choroidal volume in branch retinal vein occlusion before and after intravitreal anti-VEGF injection.
    Chung YK; Shin JA; Park YH
    Retina; 2015 Jun; 35(6):1234-9. PubMed ID: 25574783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.